NCT06334783View on ClinicalTrials.gov

TIL for Patients With Advanced Solid Tumor

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

Autologous tumor-infiltrating lymphocyte cells

On day 0, all patients will receive autologous tumor-infiltrating lymphocyte cells administered.

Trial Locations (3)

210000

RECRUITING

Nanjing Jinling Hospital, Nanjing

Unknown

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen

NOT_YET_RECRUITING

Wowen's hospital, School of medicine, Zhejiang University, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Jinling Hospital, China

OTHER

collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

collaborator

Women's Hospital School Of Medicine Zhejiang University

OTHER

lead

Hervor Therapeutics

INDUSTRY